Optimum Investment Advisors Decreases Stake in Pfizer Inc. $PFE

Optimum Investment Advisors reduced its stake in Pfizer Inc. (NYSE:PFE) by 3.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,364 shares of the biopharmaceutical company’s stock after selling 750 shares during the period. Optimum Investment Advisors’ holdings in Pfizer were worth $518,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the 1st quarter worth approximately $27,000. Curio Wealth LLC increased its stake in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the period. Bayforest Capital Ltd purchased a new position in Pfizer in the 1st quarter worth approximately $28,000. North Capital Inc. purchased a new position in Pfizer in the 1st quarter worth approximately $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $29,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on PFE shares. Morgan Stanley cut their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $28.13.

Pfizer Trading Up 0.5%

NYSE PFE opened at $24.79 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.17. The firm has a market capitalization of $140.92 billion, a PE ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. The stock’s 50 day moving average is $24.87 and its 200 day moving average is $24.18.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.60 earnings per share. The firm’s revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.